Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
08 04 2021
Historique:
pubmed: 17 3 2021
medline: 8 6 2021
entrez: 16 3 2021
Statut: ppublish

Résumé

Src homology 2 domain-containing inositol phosphate phosphatase 2 (SHIP2) is one of the 10 human inositol phosphate 5-phosphatases. One of its physiological functions is dephosphorylation of phosphatidylinositol 3,4,5-trisphosphate, PtdIns(3,4,5)P

Identifiants

pubmed: 33724834
doi: 10.1021/acs.jmedchem.0c01944
pmc: PMC7610569
mid: EMS116971
doi:

Substances chimiques

Enzyme Inhibitors 0
Fluoresceins 0
Fluorescent Dyes 0
Inositol Phosphates 0
Ligands 0
Inppl1 protein, mouse EC 3.1.3.86
Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases EC 3.1.3.86

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3813-3826

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101010
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/N002024/1
Pays : United Kingdom

Références

Med Res Rev. 2014 Jul;34(4):795-824
pubmed: 24302498
J Biol Chem. 2004 Oct 22;279(43):44987-95
pubmed: 15316017
J Immunol. 2010 Apr 1;184(7):3582-9
pubmed: 20200281
Adv Biol Regul. 2020 May;76:100651
pubmed: 31519471
Chembiochem. 2017 Feb 1;18(3):233-247
pubmed: 27907247
iScience. 2020 Aug 21;23(8):101433
pubmed: 32823063
Elife. 2017 Aug 09;6:
pubmed: 28792888
Mol Cell. 2018 Sep 20;71(6):1092-1104.e5
pubmed: 30174291
Eur J Med Chem. 2018 Sep 5;157:405-422
pubmed: 30103190
Physiology (Bethesda). 2009 Feb;24:8-16
pubmed: 19196647
FASEB J. 2007 May;21(7):1481-91
pubmed: 17264160
Curr Opin Pharmacol. 2012 Aug;12(4):444-51
pubmed: 22483603
Mol Med. 2012 Feb 10;18:65-75
pubmed: 22033675
ACS Med Chem Lett. 2019 Oct 18;11(3):309-315
pubmed: 32184962
Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):101-7
pubmed: 17164532
Eur J Pharmacol. 2010 Sep 10;642(1-3):177-82
pubmed: 20558154
Eur J Med Chem. 2013 Apr;62:649-60
pubmed: 23434638
Methods. 2011 Sep;55(1):94-106
pubmed: 21821126
Eur J Pharmacol. 1993 Feb 15;244(3):203-10
pubmed: 8384566
Methods Mol Biol. 2009;462:223-39
pubmed: 19160673
Structure. 2014 May 6;22(5):744-55
pubmed: 24704254
Bone. 2020 May;134:115244
pubmed: 31958532
Biochem J. 2020 Jul 31;477(14):2621-2638
pubmed: 32706850
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
ACS Chem Biol. 2012 May 18;7(5):822-8
pubmed: 22330088
Blood. 2007 Sep 15;110(6):1942-9
pubmed: 17502453
Org Lett. 2005 Mar 17;7(6):1073-6
pubmed: 15760142
Science. 1997 Jan 31;275(5300):665-8
pubmed: 9005852
J Hematol Oncol. 2018 May 16;11(1):66
pubmed: 29769142
Cell Signal. 2008 Apr;20(4):684-94
pubmed: 18249092
Angew Chem Int Ed Engl. 2016 Jan 26;55(5):1614-50
pubmed: 26694856
Biochemistry. 2016 Mar 8;55(9):1384-97
pubmed: 26854536
Biochem Soc Trans. 2020 Feb 28;48(1):291-300
pubmed: 32049315
SLAS Discov. 2019 Jun;24(5):515-522
pubmed: 30811960
J Med Chem. 2018 Oct 11;61(19):8838-8846
pubmed: 30160967
Exp Hematol. 2011 Jan;39(1):2-13
pubmed: 21056081
ACS Chem Biol. 2014 Jun 20;9(6):1359-68
pubmed: 24742366
Comb Chem High Throughput Screen. 2003 Jun;6(4):321-30
pubmed: 12769675
Br J Pharmacol. 2009 Oct;158(3):879-87
pubmed: 19694723
Messenger (Los Angel). 2012 Dec 1;1(2):167-181
pubmed: 24749014
Blood Cancer J. 2017 Mar 10;7(3):e539
pubmed: 28282033
Sci Rep. 2015 Aug 21;5:12949
pubmed: 26292723
Acta Crystallogr D Biol Crystallogr. 2006 Aug;62(Pt 8):915-22
pubmed: 16855309

Auteurs

Hayley Whitfield (H)

School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, U.K.

Andrew M Hemmings (AM)

School of Chemistry, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, U.K.

Stephen J Mills (SJ)

Medicinal Chemistry & Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, U.K.

Kendall Baker (K)

School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, U.K.

Gaye White (G)

School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, U.K.

Stuart Rushworth (S)

Department of Molecular Haematology; Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, U.K.

Andrew M Riley (AM)

Medicinal Chemistry & Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, U.K.

Barry V L Potter (BVL)

Medicinal Chemistry & Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, U.K.

Charles A Brearley (CA)

School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH